




RealRate

PHARMACEUTICAL 2022

IMPEL PHARMACEUTICALS INC
Rank 378 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

IMPEL PHARMACEUTICALS INC Rank 378 of 475



The relative strengths and weaknesses of IMPEL PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMPEL PHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 37% points. The greatest weakness of IMPEL PHARMACEUTICALS INC is the variable Net Income, reducing the Economic Capital Ratio by 181% points.

The company's Economic Capital Ratio, given in the ranking table, is -353%, being 77% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	94,576
Cost of Goods Sold	691
Intangible Assets	0
Liabilities, Current	15,954
Liabilities, Non-Current	29,450
Other Assets	187
Other Compr. Net Income	0
Other Expenses	2.0
Other Liabilities	0
Other Net Income	-5,048
Property and Equipment	3,149
Research and Development	20,563
Revenues	668
Selling, General and Administrative Expense	50,900

Output Variable	Value in 1000 USD
Assets	97,912
Liabilities	45,404
Expenses	72,156
Stockholders Equity	52,508
Net Income	-76,536
Comprehensive Net Income	-76,536
Economic Capital Ratio	-353%

